You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

sintilimab

Showing 1 - 25 of 163
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric Cancer Trial in Xi'an (dietary supplement, biological, drug)

Recruiting
  • Gastric Cancer
  • Taurine
  • +4 more
  • Xi'an, Shaanxi, China
    Tang-Du Hospital
Nov 2, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 30, 2023

Hepatocellular Carcinoma Trial in Hangzhou (Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Hangzhou, Zhejiang, China
    Guoliang Shao
Aug 1, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 4, 2023

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • +2 more
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)

Active, not recruiting
  • Stomach Neoplasms
  • Shanghai, China
    Renji Hospital
Apr 3, 2023

Advanced Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cryoablation, Sintilimab, Lenvatinib)

Recruiting
  • Advanced Intrahepatic Cholangiocarcinoma
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 28, 2023

Non Small Cell Lung Cancer, Propranolol Trial (Propranolol HCl, Sintilimab, Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Propranolol
  • Propranolol hydrochloride
  • +2 more
  • (no location specified)
Jul 31, 2023

Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

Recruiting
  • Advanced Biliary Tract Cancer
  • Sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 22, 2023

Colorectal Cancer Stage II, Colorectal Cancer Stage III, Mmr Deficiency Trial in Guangzhou (drug, radiation, procedure, other)

Active, not recruiting
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III
  • Guangzhou, Guangdong, China
    Medical Oncology,Sun Yat-sen University Cancer Center
Jan 29, 2023

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Advanced Biliary Tract Cancer Trial in Changsha (IBI310, sintilimab)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • Changsha, Hunan, China
    Hunan cancer Hospital
Dec 13, 2022

Stomach Tumors Trial in Wuhan (Fruquintinib, Sintilimab)

Not yet recruiting
  • Stomach Neoplasms
  • Wuhan, Hubei, China
    Wuhan Union Hospital, China
Nov 22, 2022

Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,

Not yet recruiting
  • Pancreatic Cancer, Stage IB
  • +3 more
  • sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jan 4, 2023

Liver Metastasis Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

Recruiting
  • Liver Metastasis
  • Sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

Liver Metastases, Colorectal Cancer Metastatic Trial in Shanghai (Sintilimab, Regorafenib, US/CT-guided Percutaneous

Recruiting
  • Liver Metastases
  • Colorectal Cancer Metastatic
  • Sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2023

Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 10, 2022

Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin
  • +3 more
  • (no location specified)
Nov 17, 2022

Hepatocellular Carcinoma Trial in Tianjin (Sintilimab, Bevacizumab, Liver Protective Support Therapy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 8, 2022

Oral Cavity Squamous Cell Carcinoma Trial in Yichang (Sintilimab, Radiotherapy)

Recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Sintilimab
  • Radiotherapy
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Feb 18, 2023

Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

Recruiting
  • Neuroendocrine Tumor Grade 3
  • +2 more
  • Tianjin, Tianjin, China
    Rui Liu
Nov 17, 2022

Hepatocellular Carcinoma Trial in Wuhan (HAIC, Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Nov 8, 2022